Dr. Antonia Busse
Charité – Universitätsmedizin Berlin
Antonia Busse is attending physician at the Department of Hematology, Oncology and Tumor Immunology, Charité-CBF, Berlin, Germany. She is board certified in internal medicine and hematology / medical oncology. Since her doctoral thesis she is interested in tumor immunology. Her translational research concentrated on the analyses of immune escape mechanisms, the identification of prognostic immune biomarkers, and immunomodulatory properties of cancer therapeutics that might be used in combination or sequential with immunotherapy. Another research focus is the development of T cell-based cancer immunotherapy including vaccination and adoptive T cell transfer. After her postdoctoral fellowship at the Ludwig Institute of Cancer Research, Brussels (B. van den Eynde´s lab) she established here own research group at the Charité with the main goal of developing adoptive T cell therapy for solid tumors. Currently, she is working on identification and isolation of mutation specific or virus specific T cells from solid tumor tissue and peripheral blood (Cooperation with the BIH Collaborative Research Grant “Targeting somatic mutations in human cancer by T cell receptor gene therapy”, PI Thomas Blankenstein, Peter-Michael Klötzel).
Her clinical research focus is also cancer immunotherapy and immunomonitoring. She participated in several clinical studies as sub investigator and principal investigator including phase II vaccination trials in melanoma / leukemia and clinical studies with immune checkpoint inhibitors. Clinical trials combining treatment with immune checkpoint inhibitors and dendritic cell vaccination or chemotherapy are in preparation.
At Future Medicine 2017 she will talk about "Isolation of Tumor Specific T-Cells from Patients' Tumor or Peripheral Blood"